Immunovant

IMVT

Market cap $5.96B

Immunovant slips 2.4% after batoclimab misses key phase III endpoints in thyroid eye disease trials, despite stable safety and signs of biological activity.

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript

Immunovant ​said on ‌Thursday ​that ​its therapy ⁠to ​treat a ​type of ​eye ​disease failed to ‌meet ⁠the main ​goals ​in ⁠a ​late-stage ​study.

Logos added 1.1 million shares of Immunovant last quarter, a purchase estimated at about $24.5 million based on quarterly average pricing. By quarter's end, the position had grown to roughly $35 million, reflecting both the new shares and price gains during the period.

Alpine Global Management sold 128,039 shares of Immunovant in the fourth quarter; the estimated transaction value was $2.8 million based on quarterly average prices. Meanwhile, the quarter-end position value decreased by $22 million, reflecting both trading and stock price changes.

IMVT gains 17% in three months as IMVT-1402 advances across autoimmune trials, with multiple data readouts due in 2026-2027, and $994.5M cash backing development.

NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ:IMVT) on behalf of the company's shareholders.  The investigation seeks to determine whether Immunovant, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.

Immunovant beats third-quarter estimates, raises $550M to fund IMVT-1402 through launch and advances multiple studies with key data ahead.

Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript

DURHAM, N.C., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported its financial results for the third quarter ended December 31, 2025.